Literature DB >> 25861022

Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer.

Juan Wang1, Hongtao Chen2, Yifeng Liao3, Nan Chen3, Tianze Liu4, Huitao Zhang5, Hongyu Zhang6.   

Abstract

The aim of this study was to explore the expression and clinical significance of miR-494 and PTEN (phosphatase and tensin homologue deleted on chromosome ten) in non-small cell lung cancer (NSCLC). Immunohistochemistry for PTEN and in situ hybridization (ISH) for miR-494 were performed in 92 NSCLC tissues and 10 normal lung tissues to detect their expression, and correlation between their expression with clinical characteristics and prognosis was analyzed. The expression of miR-494 was significantly higher in NSCLC than in normal lung tissues (P = 0.004). The positive expression of PTEN protein in the lung carcinoma tissues was significantly lower than that in the normal lung tissues (P = 0.013), while the level of miR-494 expression was negatively correlated with PTEN expression (r = -0.577, P < 0.01). The high positive rate of miR-494 was positively correlated with pathological TNM (p-TNM) staging and lymph node metastasis. The expression of miR-494 was negatively correlated with grade of differentiation. However, the expression of PTEN was positively correlated with grade of differentiation. Patients with over-expression of miR-494 had a shorter overall survival (OS), while the negative group of PTEN was correlated with poor OS. MiR-494 over-expression and low PTEN expression are closely related to tumor p-TNM staging and lymph node metastasis, differentiation, and OS. Combined detection of PTEN and miR-494 can aid in determining malignancy degree and the prognosis of patients with NSCLC. MiR-494 may be served as a novel prognostic factor and may lead to new treatment strategies for NSCLC.

Entities:  

Keywords:  In situ hybridization; NSCLC; PTEN; miR-494

Mesh:

Substances:

Year:  2015        PMID: 25861022     DOI: 10.1007/s13277-015-3416-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

3.  MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint.

Authors:  Alexandru V Olaru; Gabriel Ghiaur; Sumitaka Yamanaka; Delgermaa Luvsanjav; Fangmei An; Irinel Popescu; Sorin Alexandrescu; Sarah Allen; Timothy M Pawlik; Michael Torbenson; Christos Georgiades; Lewis R Roberts; Gregory J Gores; Anne Ferguson-Smith; Maria I Almeida; George A Calin; Esteban Mezey; Florin M Selaru
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

4.  miR‑494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN.

Authors:  Hai-Bing Sun; Xi Chen; Hong Ji; Tao Wu; Hong-Wei Lu; Yan Zhang; Hua Li; Yi-Ming Li
Journal:  Int J Oncol       Date:  2014-09-22       Impact factor: 5.650

5.  MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.

Authors:  Won Kyu Kim; Misun Park; Young-Kook Kim; You Kwon Tae; Han-Kwang Yang; Jae Myun Lee; Hoguen Kim
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

6.  Ionizing radiation-inducible miR-494 promotes glioma cell invasion through EGFR stabilization by targeting p190B rhoGAP.

Authors:  Seo-Young Kwak; Ji-Sook Yang; Bu-Yeon Kim; In Hwa Bae; Young-Hoon Han
Journal:  Biochim Biophys Acta       Date:  2014-03

Review 7.  MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas.

Authors:  Yingyi Wang; Xiefeng Wang; Junxia Zhang; Guan Sun; Hui Luo; Chunsheng Kang; Peiyu Pu; Tao Jiang; Ning Liu; Yongping You
Journal:  J Neurooncol       Date:  2011-08-13       Impact factor: 4.130

8.  MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN.

Authors:  Yang Liu; Lihua Lai; Qingyun Chen; Yinjing Song; Sheng Xu; Feng Ma; Xiaojian Wang; Jianli Wang; Hai Yu; Xuetao Cao; Qingqing Wang
Journal:  J Immunol       Date:  2012-04-27       Impact factor: 5.422

9.  MiR-320 and miR-494 affect cell cycles of primary murine bronchial epithelial cells exposed to benzo[a]pyrene.

Authors:  Huihan Duan; Yiguo Jiang; Hongyu Zhang; Yan Wu
Journal:  Toxicol In Vitro       Date:  2009-11-16       Impact factor: 3.500

10.  Functional elucidation of miR-494 in the tumorigenesis of nasopharyngeal carcinoma.

Authors:  Hong-Fang Duan; Xiao-Qing Li; Hong-Yi Hu; Yu-Chi Li; Zhi Cai; Xue-Shuang Mei; Peng Yu; Li-Ping Nie; Wei Zhang; Zhen-Dong Yu; Guo-Hui Nie
Journal:  Tumour Biol       Date:  2015-03-26
View more
  17 in total

1.  microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.

Authors:  Aijun Yang; Xuenan Wang; Chunna Yu; Zhenzhen Jin; Lingxia Wei; Jinghe Cao; Qin Wang; Min Zhang; Lin Zhang; Lei Zhang; Cuifang Hao
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

2.  miR-494-3p Induces Cellular Senescence and Enhances Radiosensitivity in Human Oral Squamous Carcinoma Cells.

Authors:  Jui-Hung Weng; Cheng-Chia Yu; Yueh-Chun Lee; Cheng-Wei Lin; Wen-Wei Chang; Yu-Liang Kuo
Journal:  Int J Mol Sci       Date:  2016-07-08       Impact factor: 5.923

3.  Prognostic and clinicopathological significance of microRNA-494 overexpression in cancers: a meta-analysis.

Authors:  Zhenxian Xiang; Min Sun; Zewei Yuan; Chunxiao Zhang; Jun Jiang; Sihao Huang; Bin Xiong
Journal:  Oncotarget       Date:  2017-11-03

4.  Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis.

Authors:  Yongsheng Zhao; Renyan Zheng; Jian Li; Feng Lin; Lunxu Liu
Journal:  Thorac Cancer       Date:  2017-03-06       Impact factor: 3.500

5.  miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.

Authors:  Sebastiano Rontauroli; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Samantha Ruberti; Elisa Bianchi; Simona Salati; Zelia Prudente; Chiara Rossi; Vittorio Rosti; Paola Guglielmelli; Giovanni Barosi; Alessandro Vannucchi; Enrico Tagliafico; Rossella Manfredini
Journal:  Oncotarget       Date:  2017-03-28

6.  Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathway.

Authors:  J Y Liu; Y B Dai; X Li; K Cao; D Xie; Z T Tong; Z Long; H Xiao; M K Chen; Y L Ye; B Liu; J Tan; J Tang; Z Z Xu; Y Gan; Y H Zhou; F Deng; L Y He
Journal:  Cell Death Dis       Date:  2017-03-23       Impact factor: 8.469

7.  miR-494-3p is a novel tumor driver of lung carcinogenesis.

Authors:  Alice Faversani; Stefano Amatori; Claudia Augello; Federico Colombo; Laura Porretti; Mirco Fanelli; Stefano Ferrero; Alessandro Palleschi; Pier Giuseppe Pelicci; Elena Belloni; Giulia Ercoli; Anna Degrassi; Marco Baccarin; Dario C Altieri; Valentina Vaira; Silvano Bosari
Journal:  Oncotarget       Date:  2017-01-31

8.  MIR494 reduces renal cancer cell survival coinciding with increased lipid droplets and mitochondrial changes.

Authors:  Punashi Dutta; Edward Haller; Arielle Sharp; Meera Nanjundan
Journal:  BMC Cancer       Date:  2016-01-21       Impact factor: 4.430

Review 9.  PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature.

Authors:  Jian Xiao; Cheng-Ping Hu; Bi-Xiu He; Xi Chen; Xiao-Xiao Lu; Ming-Xuan Xie; Wei Li; Shu-Ya He; Shao-Jin You; Qiong Chen
Journal:  Oncotarget       Date:  2016-09-06

10.  MicroRNA-494-3p Promotes Cell Growth, Migration, and Invasion of Nasopharyngeal Carcinoma by Targeting Sox7.

Authors:  Huiping He; Xianghui Liao; Qingmei Yang; Yuan Liu; Yan Peng; Hongzhen Zhong; Jun Yang; Huiqing Zhang; Zhonghua Yu; Yufang Zuo; Chengnong Guan; Zumin Xu
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.